Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: A nested case-control study

BMJ (Online)

Volumn 340, Issue 7742, 2010, Pages 352-

  Martinez, Carlos ^a,b   Assimes, Themistocles L ^c   Mines, Daniel ^d   Dell'Aniello, Sophie ^a   Suissa, Samy ^a  

^a MCGILL UNIVERSITY   (Canada)

^b Stanford University School of Medicine ^*  (Germany)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; DOSULEPIN; FLUOXETINE; VENLAFAXINE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DATA BASE; DEPRESSION; FEMALE; FOLLOW UP; HEART VENTRICLE TACHYCARDIA; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; SUDDEN DEATH; UNITED KINGDOM;

EID: 76649095309     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c249     Document Type: Article

References (46)

1. Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 2002;325:1332-3.
2. Morgan O, Griffiths C, Baker A, Majeed A. Fatal toxicity of antidepressants in England and Wales, 1993-2002. Health Stat Q 2004;23:18-24.
3. Cheeta S, Schifano F, Oyefeso A,Webb L,Ghodse AH. Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998-2000. Br J Psychiatry 2004;184:41-7.
4. Heerdink ER, Hugenholtz GW, Meijer WE, Egberts AC. Channelling new antidepressants to problem patients may be factor in fatal toxicity. BMJ 2003;326:600.
5. Egberts AC, Lenderink AW, de Koning FH, Leufkens HG. Channeling of three newly introduced antidepressants to patients not responding satisfactorily to previous treatment. J Clin Psychopharmacol 1997;17:149-55.
6. Khalifa M, Daleau P, Turgeon J. Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther 1999;291:280-4.
7. Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 2003;96:369-74.
8. Product Monograph Effexor XR Capsules (venlafaxine hydrochloride), extended release capsules (37.5, 75, 150 mg). www.wyeth.ca/en/products/ Product%20Monographs%20PDFs/Effexor%20PRODUCT%20MONOGRAPH%2010Jan07.pdf.
9. Electronic Medicines Compendium (eMC). Efexor-summary of product characteristics. 2008. http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc. asp?DocumentID=2209.
10. Johnson EM, Whyte E, Mulsant BH, Pollock BG, Weber E, Begley AE, et al. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am J Geriatr Psychiatry 2006;14:796-802.
11. Colbridge MG, Volans GN. Venlafaxine in overdose - experience of the National Poisons Information Service (London centre). J Toxicol Clin Toxicol 1999;37:383.
12. Kelly CA, Dhaun N, Laing WJ, Strachan FE, Good AM, Bateman DN. Comparative toxicity of citalopram and the newer antidepressants after overdose. J Toxicol Clin Toxicol 2004;42:67-71.
13. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998;59:502-8.
14. Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 1998;59:116-22.
15. Medicines and Healthcare Products Regulatory Agency. Experts complete review on safety of antidepressants. 2005. www.mhra.gov.uk/NewsCentre/ Pressreleases/CON002060.
16. Medicines and Healthcare Products Regulatory Agency. Updated summary of the Committee on Safety of Medicines meeting held on 25 November 2004. 2007. www.mhra.gov.uk/home/groups/l-cs-el/documents/committeedocument/con003208.pdf.
17. Medicines and Healthcare Products Regulatory Agency. Venlafaxine (Efexor): summary of basis for regulatory position. 2006. www.mhra.gov.uk/ Safetyinformation/Safetywarningsalertsandrecalls/ Safetywarningsandmessagesformedicines/CON2023846.
18. Wood L, Martinez C. The general practice research database: role in pharmacovigilance. Drug Saf 2004;27:871-81.
19. Rubino A, Roskell N, Tennis P, Mines D, Weich S, Andrews E. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ 2007;334:242.
20. General Practice Research Database. Facts and figures. 2009. www.gprd.com/gprd/factsandfigures.asp.
21. Essebag V, Genest J Jr, Suissa S, Pilote L. The nested case-control study in cardiology. Am Heart J 2003;146:581-90.
22. Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. In: Strom BL, ed. Pharmacoepidemiology. John Wiley & Sons, 2005:811-29.
23. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation 1998;98:2334-51.
24. Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005;330:389-93.
25. Arizona Center for Education and Research on Therapeutics. QT drug lists by risk groups: drugs that prolong the QT interval and/or induce torsades de pointes ventricular arrhythmia. www.azcert.org/medical-pros/drug-lists/drug- lists.cfm.
26. LaPointe NM, Curtis LH, Chan KA, Kramer JM, Lafata JE, Gurwitz JH, et al. Frequency of high-risk use of QT-prolonging medications. Pharmacoepidemiol Drug Saf 2006;15:361-8.
27. Rothman KJ, Greenland S, Lash TL. Case-control studies. In: Rothman KJ, Greenland S, Lash T, eds. Modern epidemiology. 3rd ed. Lippincott Williams-Wilkins, 2008:111-27.
28. MinesD,Hill D, Yu H, Novelli L. Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. Pharmacoepidemiol Drug Saf 2005;14:367-72.
29. Rowan PJ, Haas D, Campbell JA, Maclean DR, Davidson KW. Depressive symptoms have an independent, gradient risk for coronary heart disease incidence in a random, population-based sample. Ann Epidemiol 2005;15:316-20.
30. Ariyo AA, Haan M, Tangen CM, Rutledge JC, Cushman M, Dobs A, et al: Cardiovascular Health Study Collaborative Research Group. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Circulation 2000;102:1773-9.
31. Anda R, Williamson D, Jones D,Macera C, Eaker E, Glassman A, et al. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of US adults. Epidemiology 1993;4:285-94.
32. Frasure-Smith N, Lespérance F. Depression and anxiety as predictors of 2-year cardiac events in patients with stable coronary artery disease. Arch Gen Psychiatry 2008;65:62-71.
33. Buckley NA, Dawson AH, Whyte IM, Henry DA. Greater toxicity in overdose of dothiepin than of other tricyclic antidepressants. Lancet 1994;343:159-62.
34. Chan CY,WaringWS, Chan CYY, Waring WS. Images in cardiovascular medicine. Tricyclic cardiotoxicity treated with sodium bicarbonate. Circulation 2007;115:e63-4.
35. Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004;75:234-41.
36. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary: 58 (September 2009). Pharmaceutical Press, 2009.
37. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225-35.
38. Herlitz J, Engdahl J, Svensson L, Young M, Angquist KA, Holmberg S. Changes in demographic factors and mortality after out-of-hospital cardiac arrest in Sweden. Coron Artery Dis 2005;16:51-7.
39. De Maio VJ, Stiell IG, Wells GA, Spaite DW: OPALS study group. Cardiac arrest witnessed by emergency medical services personnel: descriptive epidemiology, prodromal symptoms, and predictors of survival. Ann Emerg Med 2000;35:138-46.
40. Centers for Disease Control and Prevention (CDC). State-specific mortality from sudden cardiac death-United States, 1999. MMWR Morb Mortal Wkly Rep 2002;51:123-6.
41. Pratt CM, Hertz RP, Ellis BE, Crowell SP, Louv W, Moyé L. Risk of developing life-threatening ventricular arrhythmia associated with tefenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine. Am J Cardiol 1994;73:346-52.
42. Hennessy S, Bilker WB, Knauss JS, Margolis DJ, Kimmel SE, Reynolds RF, et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ 2002;325:1070.
43. Enger C, Cali C, Walker AM. Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States. Pharmacoepidemiol Drug Saf 2002;11:477-86.
44. Walker AM, Szneke P, Weatherby LB, Dicker LW, Lanza LL, Loughlin JE, et al. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Am J Med 1999;107:356-62.
45. Hennessy S, Leonard CE, Palumbo CM, Bilker WB, Newcomb C, Kimmel SE. Diagnostic codes for sudden cardiac death and ventricular arrhythmia functioned poorly to identify outpatient events in EPIC's General Practice Research Database. Pharmacoepidemiol Drug Saf 2008;17:1131-6.
46. Nemeroff CB, Entsuah R, Benattia I, Demitrack M, Sloan DM, Thase ME. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 2008;63:424-34.